NeuroVive Pharmaceutical AB EBITDA margin
What is the EBITDA margin of NeuroVive Pharmaceutical AB?
The EBITDA margin of NeuroVive Pharmaceutical AB is -79,544.30%
What is the definition of EBITDA margin?
EBITDA margin is a profitability ratio that measures how much EBITDA the company generates as a percentage of revenue.
ttm (trailing twelve months)
EBITDA margin measures how much of EBITDA is generated as a percentage of sales. It measures the company’s operating profit as a percentage of its revenue and is calculated as EBITDA (earnings before interest, taxes, depreciation, and amortization) divided by total revenue.
EBITDA margin also helps with judging the effectiveness of cost-cutting processes at the company. The higher the company’s EBITDA margin, the lower operating expenses are in respect to revenue. As a result, a higher EBITDA margin is considered more favorable. Smaller companies can have higher EBITDA margins since they are able to operate more efficiently and maximize their profitability.
EBITDA excludes interest on debt, taxes, and capital expenditures, the margin does not provide a perfectly clear estimate of the business’s cash flow generation. Furthermore, EBITDA margin is not recognized as a GAAP (generally accepted accounting principles) metric.
EBITDA margin of companies in the Health Care sector on OTC compared to NeuroVive Pharmaceutical AB
What does NeuroVive Pharmaceutical AB do?
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Companies with ebitda margin similar to NeuroVive Pharmaceutical AB
- Eagle Mountain Mining has EBITDA margin of -80,928.28%
- RosCan Gold has EBITDA margin of -80,206.96%
- Cannonau has EBITDA margin of -80,183.27%
- Revolution Medicines Inc has EBITDA margin of -80,180.19%
- NeuroVive Pharmaceutical AB has EBITDA margin of -79,734.59%
- Carbios SA has EBITDA margin of -79,708.33%
- NeuroVive Pharmaceutical AB has EBITDA margin of -79,544.30%
- CropLogic has EBITDA margin of -79,147.31%
- Seneca Biopharma Inc has EBITDA margin of -78,278.65%
- Karuna Therapeutics Inc has EBITDA margin of -75,393.88%
- Accelerate Resources has EBITDA margin of -75,249.13%
- Pacific American has EBITDA margin of -72,236.00%
- Mako Gold has EBITDA margin of -72,194.15%